https://www.selleckchem.com/pr....oducts/adavivint.htm
© 2020 Rahman et al.Introduction This retrospective, observational cohort study utilized an integrated dataset from an electronic health records system and a claims database to describe demographic and clinical characteristics, healthcare resource utilization (HCRU), and treatment patterns in COPD patients initiating long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist (LABA) fixed-dose combination (FDC) treatment in the USA. Methods Patients were aged ≥40 years and had a COPD diagnosis (Practice Fusion system) and ≥1 presc
Like
Comment
Share
